Insider Transactions in Q4 2021 at Neogenomics Inc (NEO)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2021
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,572
+42.0%
|
-
|
|
Dec 30
2021
|
Halley E Gilbert Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,858
+30.38%
|
-
|
|
Dec 30
2021
|
Cynthia J Dieter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,643
+44.76%
|
-
|
|
Dec 30
2021
|
Jennifer Balliet VP and Chief Culture Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,400
+30.56%
|
-
|
|
Dec 30
2021
|
William Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,400
+25.7%
|
-
|
|
Dec 30
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
30,572
+39.28%
|
-
|
|
Dec 30
2021
|
George Cardoza President & COO, Lab Ops |
BUY
Grant, award, or other acquisition
|
Direct |
61,143
+19.94%
|
-
|
|
Dec 30
2021
|
Mark Mallon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
152,858
+40.39%
|
-
|
|
Dec 30
2021
|
Clive Morris President of Inivata |
BUY
Grant, award, or other acquisition
|
Direct |
30,572
+42.55%
|
-
|
|
Dec 30
2021
|
Gina M Wallar President, Pharma Services |
BUY
Grant, award, or other acquisition
|
Direct |
15,286
+41.78%
|
-
|
|
Dec 22
2021
|
Kevin C Johnson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+8.19%
|
$23,338
$7.27 P/Share
|
|
Dec 22
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.05%
|
$45,000
$9.07 P/Share
|
|
Dec 21
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
SELL
Open market or private sale
|
Direct |
1,846
-13.64%
|
$64,610
$35.0 P/Share
|
|
Dec 06
2021
|
Mark Mallon Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
17,000
+18.94%
|
$510,000
$30.63 P/Share
|
|
Nov 30
2021
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+38.18%
|
$175,000
$7.52 P/Share
|
|
Nov 26
2021
|
Douglas Matthew Brown Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
33,334
-74.11%
|
$1,200,024
$36.85 P/Share
|
|
Nov 24
2021
|
William Bonello Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-61.77%
|
$925,000
$37.13 P/Share
|
|
Nov 24
2021
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+38.18%
|
$200,000
$8.03 P/Share
|
|
Nov 24
2021
|
Douglas Matthew Brown Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
33,333
-42.56%
|
$1,199,988
$36.84 P/Share
|
|
Nov 23
2021
|
Douglas Matthew Brown Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
33,333
-29.86%
|
$1,233,321
$37.19 P/Share
|
|
Nov 10
2021
|
David Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,623
+50.0%
|
-
|
|
Oct 11
2021
|
Lynn A. Tetrault Director |
BUY
Grant, award, or other acquisition
|
Direct |
838
+2.29%
|
-
|